Loss of ASRGL1 expression is an independent biomarker for disease-specific survival in endometrioid endometrial carcinoma - UTU Research Portal

A1 Refereed original research article in a scientific journal

Loss of ASRGL1 expression is an independent biomarker for disease-specific survival in endometrioid endometrial carcinoma

Authors: Edqvist PHD, Huvila J, Forsstrom B, Talve L, Carpen O, Salvesen HB, Krakstad C, Grenman S, Johannesson H, Ljungqvist O, Uhlen M, Ponten F, Auranen A

Publisher: ACADEMIC PRESS INC ELSEVIER SCIENCE

Publication year: 2015

Journal: Gynecologic Oncology

Journal name in source: GYNECOLOGIC ONCOLOGY

Journal acronym: GYNECOL ONCOL

Volume: 137

Issue: 3

First page : 529

Last page: 537

Number of pages: 9

ISSN: 0090-8258

DOI: https://doi.org/10.1016/j.ygyno.2015.03.055(external)

Abstract

Conclusions. Loss of ASRGL1 in EEA is a powerful biomarker for poor prognosis and retained ASRGL1 has a positive impact on survival. ASRGL1 immunohistochemistry has potential to become an additional tool for prognostication in cases where tailoring adjuvant treatment according to additional prognostic factors besides grade and stage is recommended. (C) 2015 Elsevier Inc. All rights reserved.